CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.
Novartis has confirmed that it will shed around 8,000 jobs across its global operations as part of a restructure first announced in April.
That involves the creation of a new organizational structure and operating model to improve growth and productivity and a merging of Novartis’s pharmaceuticals and oncology business units into a single innovative medicines business across all markets
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ‘historic economic prosperity deal’ does not include the sector.
